NRG Therapeutics secured $67 million in a funding round featuring Merck KGaA and Novartis venture arms, supporting development of its mitochondrial-targeted therapies for neurodegenerative diseases including Parkinson’s and amyotrophic lateral sclerosis (ALS). The company targets mitochondrial dysfunction pathways implicated in these disorders and aims to enter clinical trials within a year. This investment underscores growing interest in mitochondrial medicine as a novel frontier in neurodegenerative disease treatment.